Literature DB >> 19712770

Immunogenicity of bacteriophage lambda particles displaying porcine Circovirus 2 (PCV2) capsid protein epitopes.

Lakshman N A Gamage1, John Ellis, Sidney Hayes.   

Abstract

Phage lambda particles displaying four immunodominant regions of porcine Circovirus 2 (PCV2) capsid protein (LDP-D-CAP) was shown to be immunogenic in pigs. The immunodominant regions were fused to the carboxyl-terminal of lambda head protein D. Expression of D-CAP on lambda display particles was demonstrated by ELISA and Western blots. Pigs receiving LDP-D-CAP, without incorporating adjuvant, showed significant anti-PCV2 immune response following the primary vaccination. The LDP-D-CAP preparation induced PCV2 neutralizing antibodies. Delayed type hypersensitivity (DTH) reaction scores revealed that the immunized pigs were hypersensitive to both lambda phage and PCV2 antigens. The LDP-D-CAP elicited both cellular and humoral immune responses. Neither LDP-D-CAP nor the lambda control elicited any untoward local or systemic reactions following immunization. These studies produced the first potential phage vaccine to porcine Circovirus 2.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19712770     DOI: 10.1016/j.vaccine.2009.08.019

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  The 2.3-angstrom structure of porcine circovirus 2.

Authors:  Reza Khayat; Nicholas Brunn; Jeffrey A Speir; John M Hardham; Robert G Ankenbauer; Anette Schneemann; John E Johnson
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Dense display of HIV-1 envelope spikes on the lambda phage scaffold does not result in the generation of improved antibody responses to HIV-1 Env.

Authors:  Jonelle Mattiacio; Scott Walter; Matt Brewer; William Domm; Alan E Friedman; Stephen Dewhurst
Journal:  Vaccine       Date:  2011-02-18       Impact factor: 3.641

Review 3.  Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases.

Authors:  Pan Tao; Jingen Zhu; Marthandan Mahalingam; Himanshu Batra; Venigalla B Rao
Journal:  Adv Drug Deliv Rev       Date:  2018-07-06       Impact factor: 15.470

4.  Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge.

Authors:  Hamidreza Hashemi; Somayeh Pouyanfard; Mojgan Bandehpour; Zahra Noroozbabaei; Bahram Kazemi; Xavier Saelens; Talat Mokhtari-Azad
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

5.  A CI-independent form of replicative inhibition: turn off of early replication of bacteriophage lambda.

Authors:  Sidney Hayes; Monique A Horbay; Connie Hayes
Journal:  PLoS One       Date:  2012-05-10       Impact factor: 3.240

6.  Simultaneous display of two large proteins on the head and tail of bacteriophage lambda.

Authors:  Emiliano Pavoni; Paola Vaccaro; Valeria D'Alessio; Rita De Santis; Olga Minenkova
Journal:  BMC Biotechnol       Date:  2013-09-30       Impact factor: 2.563

7.  Bacterial Virus Lambda Gpd-Fusions to Cathelicidins, α- and β-Defensins, and Disease-Specific Epitopes Evaluated for Antimicrobial Toxicity and Ability to Support Phage Display.

Authors:  Sidney Hayes
Journal:  Viruses       Date:  2019-09-17       Impact factor: 5.048

8.  A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display.

Authors:  Krista G Freeman; Katherine S Wetzel; Yu Zhang; Kira M Zack; Deborah Jacobs-Sera; Sara M Walters; Dominique J Barbeau; Anita K McElroy; John V Williams; Graham F Hatfull
Journal:  Microorganisms       Date:  2021-11-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.